Immunotherapy: State-of-the-art review of therapies and theratypes
Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is currently supported by novel modalities such as mAb-based therapies or small molecules targeting the key nodes of the allergic inflammation...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology Jg. 150; H. 6; S. 1279 - 1288 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Elsevier Inc
01.12.2022
|
| Schlagworte: | |
| ISSN: | 0091-6749, 1097-6825, 1097-6825 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is currently supported by novel modalities such as mAb-based therapies or small molecules targeting the key nodes of the allergic inflammation network. In this review, a summary of the most significant advances in immunotherapy is presented, addressing not only novel approaches to stratifying patients but also major controlled clinical trials and real-world evidence that strengthen the role of immunotherapy in the treatment of allergies. |
|---|---|
| AbstractList | Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is currently supported by novel modalities such as mAb-based therapies or small molecules targeting the key nodes of the allergic inflammation network. In this review, a summary of the most significant advances in immunotherapy is presented, addressing not only novel approaches to stratifying patients but also major controlled clinical trials and real-world evidence that strengthen the role of immunotherapy in the treatment of allergies. Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is currently supported by novel modalities such as mAb-based therapies or small molecules targeting the key nodes of the allergic inflammation network. In this review, a summary of the most significant advances in immunotherapy is presented, addressing not only novel approaches to stratifying patients but also major controlled clinical trials and real-world evidence that strengthen the role of immunotherapy in the treatment of allergies.Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is currently supported by novel modalities such as mAb-based therapies or small molecules targeting the key nodes of the allergic inflammation network. In this review, a summary of the most significant advances in immunotherapy is presented, addressing not only novel approaches to stratifying patients but also major controlled clinical trials and real-world evidence that strengthen the role of immunotherapy in the treatment of allergies. |
| Author | Shamji, Mohamed H. Zemelka-Wiącek, Magdalena Agache, Ioana Jutel, Marek |
| Author_xml | – sequence: 1 givenname: Ioana surname: Agache fullname: Agache, Ioana email: ibrumaru@unitbv.ro organization: Faculty of Medicine, Transylvania University, Brasov, Romania – sequence: 2 givenname: Magdalena surname: Zemelka-Wiącek fullname: Zemelka-Wiącek, Magdalena organization: Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland – sequence: 3 givenname: Mohamed H. surname: Shamji fullname: Shamji, Mohamed H. organization: National Heart and Lung Institute, Imperial College London, London, United Kingdom – sequence: 4 givenname: Marek surname: Jutel fullname: Jutel, Marek organization: Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36328808$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkLtOwzAUQC0EgvL4AQaUkSXFjyROEAsgHpUqMQCz5djXwiWJi-2C-ve4CjAwwGTdq3Ou5LOPtgc3AELHBE8JJtXZYrqQyk4ppjQtphjzLTQhuOF5VdNyG00wbkhe8aLZQ_shLHCaWd3soj1WMVrXuJ6gq1nfrwYXX8DL5fo8e4wyQu5Mnja59DHz8G7hI3MmGxkLIZODHqe4XkI4RDtGdgGOvt4D9Hx783R9n88f7mbXl_NcFZzF3BBmSkUUbbGGVgOrDSWF0Y3RFFrZ4qrkRclKQjltgTGlOeMFVlwSqaQs2QE6He8uvXtbQYiit0FB18kB3CoIyhktGWcVTujJF7pqe9Bi6W0v_Vp8_zsBdASUdyF4MD8IwWITVyzEJq7YxN3sUtwk1b8kZVMu64bope3-Vi9GFVKgFNSLoCwMCrT1oKLQzv6tn__SVWcHq2T3Cuv_5E8c96g5 |
| CitedBy_id | crossref_primary_10_3390_jcm13237268 crossref_primary_10_1016_j_jaci_2025_03_025 crossref_primary_10_1016_j_jaip_2023_08_029 crossref_primary_10_3390_ijms26125660 crossref_primary_10_1007_s13555_024_01193_1 crossref_primary_10_3390_molecules28031360 crossref_primary_10_1007_s00432_024_05791_6 crossref_primary_10_1016_j_jaip_2023_11_031 crossref_primary_10_1111_all_15889 crossref_primary_10_1016_j_tifs_2025_104865 crossref_primary_10_1097_ACI_0000000000000925 crossref_primary_10_1111_all_15945 crossref_primary_10_1007_s11882_023_01067_0 crossref_primary_10_1016_j_cej_2024_152675 crossref_primary_10_1111_all_16518 crossref_primary_10_1039_D4BM01532K crossref_primary_10_1080_1744666X_2024_2406894 |
| Cites_doi | 10.1111/all.14639 10.1016/j.jaci.2020.10.029 10.5414/ALX02262E 10.1038/s41467-021-27397-z 10.3390/genes12020208 10.1016/j.jaci.2016.08.017 10.1021/acsnano.0c07781 10.1016/S2213-2600(21)00226-5 10.1016/j.jaci.2020.07.036 10.1172/JCI149336 10.1111/all.15295 10.1016/j.jaci.2020.07.011 10.1016/j.jaci.2022.01.011 10.1136/thoraxjnl-2020-215168 10.3389/fimmu.2021.744544 10.1016/j.jaci.2021.02.009 10.3389/fimmu.2022.912529 10.1172/JCI124611 10.1016/j.jaci.2021.03.044 10.1056/NEJMoa2030880 10.1016/j.jaci.2020.11.027 10.1016/j.biopha.2019.109685 10.1016/j.jaci.2021.02.038 10.1152/ajplung.00059.2016 10.1016/j.jaip.2020.08.015 10.1016/j.jaip.2021.06.060 10.1016/j.immuni.2020.12.013 10.1111/cea.14014 10.1016/S2213-2600(21)00167-3 10.1016/j.jaci.2021.08.030 10.1016/j.jaci.2021.03.030 10.1016/j.jaci.2020.11.011 10.1183/13993003.04605-2020 10.1002/iid3.585 10.1056/NEJMoa2024257 10.1016/j.jaci.2022.01.012 10.1111/pai.13517 10.1177/19458924211050547 10.1016/j.clim.2021.108820 10.1159/000512561 10.1016/j.jaci.2020.08.039 10.1111/all.14753 10.1097/DER.0000000000000764 10.1016/j.jaci.2020.05.037 10.1111/pai.13569 10.1016/j.jaad.2018.01.016 10.1016/j.jaci.2020.08.004 10.1016/j.jaci.2014.02.005 10.1016/j.jaci.2021.06.012 10.1016/j.jaci.2021.08.006 10.3390/vaccines10010133 10.1016/j.anai.2020.12.016 10.1016/j.jaci.2021.02.039 10.1016/j.jaip.2021.09.023 10.1016/j.jaci.2022.05.025 10.1016/j.jaci.2020.08.042 10.1016/j.jaci.2021.05.039 10.1016/j.jaip.2021.10.060 10.1097/ACI.0000000000000782 10.1111/cea.13867 10.1016/j.jaip.2021.01.028 10.1016/j.jaci.2020.07.002 10.1016/j.jaip.2020.11.046 10.1016/j.jaci.2021.12.780 10.1111/imcb.12347 10.1016/j.rmed.2021.106332 10.1038/s41586-020-2246-4 10.1183/13993003.03969-2020 10.1111/all.14264 10.1016/j.jaci.2020.08.002 10.1016/j.jaip.2020.10.045 10.1016/j.jaci.2020.11.005 10.1056/NEJMoa2106567 10.1016/j.jaci.2020.10.035 10.1016/j.jaci.2021.04.010 10.1016/j.jaci.2021.10.023 10.1016/j.stem.2020.09.017 10.1016/j.jaci.2021.02.042 10.1016/j.jaip.2021.03.045 10.1016/j.jaip.2021.02.059 10.1016/j.jaci.2021.09.029 10.1111/all.15374 10.1016/j.jaci.2022.01.009 10.3390/vaccines9040359 10.1111/all.14478 10.1111/all.14872 10.3390/metabo11090613 10.1007/s00018-022-04366-3 10.1111/resp.13527 10.1002/rcr2.717 |
| ContentType | Journal Article |
| Copyright | 2022 American Academy of Allergy, Asthma & Immunology Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved. |
| Copyright_xml | – notice: 2022 American Academy of Allergy, Asthma & Immunology – notice: Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.jaci.2022.10.007 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6825 |
| EndPage | 1288 |
| ExternalDocumentID | 36328808 10_1016_j_jaci_2022_10_007 S0091674922013744 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Allergy Therapeutics funderid: https://doi.org/10.13039/100017255 – fundername: Medical Research Council funderid: https://doi.org/10.13039/501100000265 – fundername: Ministry of Science and Higher Education funderid: https://doi.org/10.13039/501100004569 – fundername: Laboratorios LETI – fundername: Rovolo Biotherapeutics and lecture – fundername: Romanian Ministry of Education and Research – fundername: Immune Tolerance Network funderid: https://doi.org/10.13039/100014247 |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN ADXHL AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~HD ~KM AACTN RIG 9DU AAYXX CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c473t-f13f5c1c2b0debde38f214fd9fd2ebab065745351272be33cd73740c7a1acaa53 |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000942834800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0091-6749 1097-6825 |
| IngestDate | Sun Sep 28 09:02:11 EDT 2025 Thu Apr 03 07:08:53 EDT 2025 Sat Nov 29 07:25:19 EST 2025 Tue Nov 18 22:19:38 EST 2025 Sun Apr 06 06:53:32 EDT 2025 Tue Oct 14 19:30:30 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | ILC HETE HDM immunotherapy TFH miRNA SCIT T2 CRISPR RWE TFR SLIT AD biomarkers Treg AIT endotypes biologicals AR CAR EAR OIT LAR theratype cTFH Allergen DC |
| Language | English |
| License | Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c473t-f13f5c1c2b0debde38f214fd9fd2ebab065745351272be33cd73740c7a1acaa53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 36328808 |
| PQID | 2732537360 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2732537360 pubmed_primary_36328808 crossref_primary_10_1016_j_jaci_2022_10_007 crossref_citationtrail_10_1016_j_jaci_2022_10_007 elsevier_sciencedirect_doi_10_1016_j_jaci_2022_10_007 elsevier_clinicalkey_doi_10_1016_j_jaci_2022_10_007 |
| PublicationCentury | 2000 |
| PublicationDate | December 2022 2022-12-00 20221201 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: December 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of allergy and clinical immunology |
| PublicationTitleAlternate | J Allergy Clin Immunol |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Zhu, Gao, Zhang, Chen (bib38) 2022; 36 Laoubi L, Lacoffrette M, Valsesia S, Lenief V, Guironnet-Paquet A, Mosnier A, et al. Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsets [published online ahead of print June 30, 2022]. J Allergy Clin Immunol. Skaarup, Schmid, Skjold, Graumann, Hoffmann (bib40) 2021; 147 Benito-Villalvilla, Pérez-Diego, Angelina, Kisand, Rebane, Subiza (bib8) 2022; 149 Anvari, Watkin, Rajapakshe, Hassan, Schuster, Coarfa (bib4) 2021; 230 Hoshino, Akitsu, Kubota, Ohtawa (bib13) 2021; 9 Yu, Liu, Mo, Luo, Liu, Wu (bib86) 2020; 98 Braithwaite, Cai, Tom, Galanter, Owen, Zhu (bib55) 2021; 148 Scurlock, Burks, Sicherer, Leung, Kim, Henning (bib32) 2021; 147 Gevaert, De Craemer, De Ruyck, Rottey, de Hoon, Hellings (bib45) 2022; 149 Azzano, Paquin, Langlois, Morin, Parizeault, Lacombe-Barrios (bib29) 2021; 147 Chiu, Liao, Hsu, Chiang (bib89) 2022; 79 Bacharier, Maspero, Katelaris, Fiocchi, Gagnon, de Mir (bib48) 2021; 385 Ibáñez-Sandín, Escudero, Candón Morillo, Lasa, Marchán-Martín, Sánchez-García (bib62) 2021; 32 Arasi, Castelli, Di Fraia, Villalta, Tripodi, Perna (bib71) 2021; 51 Bernstein, Epstein (bib69) 2022; 149 Leonard, Laubach, Wang (bib68) 2021; 147 Golebski, Layhadi, Sahiner, Steveling-Klein, Lenormand, Li (bib10) 2021; 54 Al-Shaikhly, MacDonald, Bammler, Altman, Ayars, Petroni (bib28) 2021; 51 Berin, Agashe, Burks, Chiang, Davidson, Dawson (bib12) 2022; 149 de Blay, Gherasim, Casale, Doyen, Bernstein (bib17) 2022; 149 DunnGalvin, Fleischer, Campbell, O’B Hourihane, Green, Sampson (bib33) 2021; 9 Padró, Gutiérrez, Moreno, Parra, Rial, Lleonart (bib42) 2022; 10 Langer, Cardili, Melo, Ferriani, Moreno, Dias (bib37) 2022; 10 Traina, Martelli, Barberi, Licari, Marseglia, Tosca (bib43) 2021; 92 Esmaeilzadeh, Tahmasebi, Athari (bib81) 2020; 123 Reiber, Wolf, Futschik, Schwab, Hölscher, Schnitker (bib58) 2021; 9 Maspero, FitzGerald, Pavord, Rice, Maroni, Rowe (bib49) 2021; 76 Siegels, Haufe, Heinrich, Werfel, Weidinger, Schmitt (bib75) 2021; 5 Bovermann, Ricklefs, Vogelberg, Klimek, Kopp (bib44) 2021; 182 Bellinghausen, Khatri, Saloga (bib59) 2022; 13 Farraia, Paciência, Castro Mendes, Cavaleiro Rufo, Shamji, Agache (bib74) 2022; 77 Shamji, Larson, Eifan, Scadding, Qin, Lawson (bib5) 2021; 148 Moses, Kaur (bib84) 2019; 24 McDonald, Urroz, Bajc, Rutherford, Brooker, Gibson (bib23) 2021; 9 Thomas, Harvey, McDonald, Stevens, Upham, Katelaris (bib66) 2021; 9 Demoly, Corren, Creticos, De Blay, Gevaert, Hellings (bib36) 2021; 147 . Cortez, Montauti, Shifrut, Gatchalian, Zhang, Shaked (bib80) 2020; 582 Carter, Maric, Brittain, Bai, Lumbard, Bolan (bib46) 2021; 147 Busse, Bleecker, FitzGerald, Ferguson, Barker, Brooks (bib50) 2021; 148 Longo, Longo, Colombo (bib77) 2021; 21 Nakajima, Matsuyama, Arai, Yamada, Hyodo, Nonaka (bib22) 2021; 147 Graff, Brusselle, Hanon, Sohy, Dupont, Peche (bib65) 2022; 10 Akinfenwa, Huang, Linhart, Focke-Tejkl, Vrtala, Poroshina (bib73) 2021; 12 Agache, Akdis (bib19) 2019; 129 Jones, Sicherer, Burks, Leung, Lindblad, Dawson (bib31) 2017; 139 de Vos, Viswanathan, Pichardo, Nazari, Jorge, Ren (bib39) 2021; 126 MacGlashan, Saini, Schroeder (bib27) 2021; 147 Brown, Baker, Vereda, Beyer, Burks, du Toit (bib34) 2022; 149 Busse, Paggiaro, Muñoz, Casale, Castro, Canonica (bib30) 2021; 58 Badi, Pavel, Pavlidis, Riley, Bates, Kermani (bib56) 2022; 149 Trichot, Faucheux, Karpf, Grandclaudon, Pattarini, Bagot (bib25) 2021; 147 Wu, Kamimoto, Zhang, Yang, Keeler, Gerovac (bib88) 2021; 131 Majchrzak-Celińska, Warych, Szoszkiewicz (bib82) 2021; 12 Song, Cano-Rodriquez, Winkle, Gjaltema, Goubert, Jurkowski (bib83) 2017; 312 Eggel, Baravalle, Hobi, Kim, Buschor, Forrer (bib90) 2014; 133 Rabe, Celli, Wechsler, Abdulai, Luo, Boomsma (bib53) 2021; 9 Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract 2021;9:2680-8.e7. Erratum in: J Allergy Clin Immunol Pract 2021;9:4182. Hawkins, Suzuki, Beermann, Barillà, Wang, Villacorta-Martin (bib87) 2021; 28 Borg, Løkke, Hilberg (bib63) 2021; 178 Nieto, Mazón, Nieto, Ibáñez, Jang, Calaforra (bib41) 2022; 77 Mikus, Zandian, Sjöberg, Hamsten, Forsström, Andersson (bib18) 2021; 147 Schmid, Würtzen, Siddhuraj, Jogdand, Petersen, Dahl (bib14) 2021; 76 Yonekura, Gotoh, Kaneko, Maekawa, Okubo, Okamoto (bib72) 2021; 9 Yao, Chen, Yu, Liu (bib1) 2021; 76 Zbären, Brigger, Bachmann, Helbling, Jörg, Horn (bib20) 2022; 149 Jackson, Busby, Pfeffer, Menzies-Gow, Brown, Gore (bib64) 2021; 76 Wechsler, Ruddy, Pavord, Israel, Rabe, Ford (bib51) 2021; 385 Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9:1299-312. Erratum in: Lancet Respir Med 2021;9:e106. Tian, Peng, Liu, Tian, Xie, Wang (bib11) 2022; 149 Thi, Suys, Lee, Nguyen, Park, Truong (bib76) 2021; 9 Roth-Walter, Adcock, Benito-Villalvilla, Bianchini, Bjermer, Boyman (bib79) 2021; 76 Boonpiyathad, Tantilipikorn, Ruxrungtham, Pradubpongsa, Mitthamsiri, Piedvache (bib9) 2021; 147 Yoneyama, Nakano, Hara, Yamada, Izawa, Uchida (bib6) 2021; 147 Sharif, Acharya, Dhondalay, Varricchi, Krasner-Macleod, Laisuan (bib2) 2021; 147 Eljaszewicz, Ruchti, Radzikowska, Globinska, Boonpiyathad, Gschwend (bib3) 2021; 147 Johal, Chichester, Oliver, Devine, Bieneman, Schroeder (bib26) 2021; 147 Engeroff, Vogel (bib85) 2022; 10 Pennington, Gasser, Kleinboelting, Zhang, Skiniotis, Eggel (bib91) 2021; 12 Guttman-Yassky, Brunner, Neumann, Khattri, Pavel, Malik (bib60) 2018; 78 Zheng, Bian, Zhai, Li, Li, Hao (bib15) 2021; 32 Zheng, Yan, Zhang, Huang, Luo, Xue (bib16) 2021; 11 Kelsen, Agache, Soong, Israel, Chupp, Cheung (bib54) 2021; 148 Gavitt, Hartmann, Sawant, Mara, Szczepanek, Rouge (bib78) 2021; 15 Mikhaylov, Del Duca, Olesen, He, Wu, Ungar (bib24) 2021; 32 Soller, Abrams, Carr, Kapur, Rex, Leo (bib61) 2021; 9 Dantzer, Dunlop, Psoter, Keet, Wood (bib35) 2022; 149 Weckmann, Bahmer, Sand, Rank Rønnow, Pech, Vermeulen (bib21) 2021; 58 van der Valk, Kappen, Ruikes-Mertens, van Maaren, Bindels, van Wijk (bib70) 2021; 76 Bachert, Han, Desrosiers, Gevaert, Heffler, Hopkins (bib47) 2022; 149 Brightling, Nair, Cousins, Louis, Singh (bib52) 2021; 385 Longo (10.1016/j.jaci.2022.10.007_bib77) 2021; 21 Guttman-Yassky (10.1016/j.jaci.2022.10.007_bib60) 2018; 78 Hoshino (10.1016/j.jaci.2022.10.007_bib13) 2021; 9 Bovermann (10.1016/j.jaci.2022.10.007_bib44) 2021; 182 Mikhaylov (10.1016/j.jaci.2022.10.007_bib24) 2021; 32 van der Valk (10.1016/j.jaci.2022.10.007_bib70) 2021; 76 Engeroff (10.1016/j.jaci.2022.10.007_bib85) 2022; 10 10.1016/j.jaci.2022.10.007_bib7 de Vos (10.1016/j.jaci.2022.10.007_bib39) 2021; 126 Skaarup (10.1016/j.jaci.2022.10.007_bib40) 2021; 147 Zheng (10.1016/j.jaci.2022.10.007_bib16) 2021; 11 Akinfenwa (10.1016/j.jaci.2022.10.007_bib73) 2021; 12 de Blay (10.1016/j.jaci.2022.10.007_bib17) 2022; 149 Leonard (10.1016/j.jaci.2022.10.007_bib68) 2021; 147 Weckmann (10.1016/j.jaci.2022.10.007_bib21) 2021; 58 Jackson (10.1016/j.jaci.2022.10.007_bib64) 2021; 76 Azzano (10.1016/j.jaci.2022.10.007_bib29) 2021; 147 Johal (10.1016/j.jaci.2022.10.007_bib26) 2021; 147 Borg (10.1016/j.jaci.2022.10.007_bib63) 2021; 178 Busse (10.1016/j.jaci.2022.10.007_bib50) 2021; 148 DunnGalvin (10.1016/j.jaci.2022.10.007_bib33) 2021; 9 Siegels (10.1016/j.jaci.2022.10.007_bib75) 2021; 5 10.1016/j.jaci.2022.10.007_bib67 Tian (10.1016/j.jaci.2022.10.007_bib11) 2022; 149 Wu (10.1016/j.jaci.2022.10.007_bib88) 2021; 131 Zheng (10.1016/j.jaci.2022.10.007_bib15) 2021; 32 Bachert (10.1016/j.jaci.2022.10.007_bib47) 2022; 149 Ibáñez-Sandín (10.1016/j.jaci.2022.10.007_bib62) 2021; 32 Nieto (10.1016/j.jaci.2022.10.007_bib41) 2022; 77 Scurlock (10.1016/j.jaci.2022.10.007_bib32) 2021; 147 Carter (10.1016/j.jaci.2022.10.007_bib46) 2021; 147 Bacharier (10.1016/j.jaci.2022.10.007_bib48) 2021; 385 Reiber (10.1016/j.jaci.2022.10.007_bib58) 2021; 9 Yao (10.1016/j.jaci.2022.10.007_bib1) 2021; 76 Wechsler (10.1016/j.jaci.2022.10.007_bib51) 2021; 385 Chiu (10.1016/j.jaci.2022.10.007_bib89) 2022; 79 Shamji (10.1016/j.jaci.2022.10.007_bib5) 2021; 148 Demoly (10.1016/j.jaci.2022.10.007_bib36) 2021; 147 MacGlashan (10.1016/j.jaci.2022.10.007_bib27) 2021; 147 Bernstein (10.1016/j.jaci.2022.10.007_bib69) 2022; 149 Arasi (10.1016/j.jaci.2022.10.007_bib71) 2021; 51 Thi (10.1016/j.jaci.2022.10.007_bib76) 2021; 9 Esmaeilzadeh (10.1016/j.jaci.2022.10.007_bib81) 2020; 123 Brightling (10.1016/j.jaci.2022.10.007_bib52) 2021; 385 McDonald (10.1016/j.jaci.2022.10.007_bib23) 2021; 9 Gavitt (10.1016/j.jaci.2022.10.007_bib78) 2021; 15 Nakajima (10.1016/j.jaci.2022.10.007_bib22) 2021; 147 Maspero (10.1016/j.jaci.2022.10.007_bib49) 2021; 76 Majchrzak-Celińska (10.1016/j.jaci.2022.10.007_bib82) 2021; 12 Traina (10.1016/j.jaci.2022.10.007_bib43) 2021; 92 10.1016/j.jaci.2022.10.007_bib57 Roth-Walter (10.1016/j.jaci.2022.10.007_bib79) 2021; 76 Moses (10.1016/j.jaci.2022.10.007_bib84) 2019; 24 Bellinghausen (10.1016/j.jaci.2022.10.007_bib59) 2022; 13 Boonpiyathad (10.1016/j.jaci.2022.10.007_bib9) 2021; 147 Zbären (10.1016/j.jaci.2022.10.007_bib20) 2022; 149 Sharif (10.1016/j.jaci.2022.10.007_bib2) 2021; 147 Agache (10.1016/j.jaci.2022.10.007_bib19) 2019; 129 Hawkins (10.1016/j.jaci.2022.10.007_bib87) 2021; 28 Anvari (10.1016/j.jaci.2022.10.007_bib4) 2021; 230 Al-Shaikhly (10.1016/j.jaci.2022.10.007_bib28) 2021; 51 Berin (10.1016/j.jaci.2022.10.007_bib12) 2022; 149 Eggel (10.1016/j.jaci.2022.10.007_bib90) 2014; 133 Cortez (10.1016/j.jaci.2022.10.007_bib80) 2020; 582 Eljaszewicz (10.1016/j.jaci.2022.10.007_bib3) 2021; 147 Rabe (10.1016/j.jaci.2022.10.007_bib53) 2021; 9 Kelsen (10.1016/j.jaci.2022.10.007_bib54) 2021; 148 Brown (10.1016/j.jaci.2022.10.007_bib34) 2022; 149 Thomas (10.1016/j.jaci.2022.10.007_bib66) 2021; 9 Soller (10.1016/j.jaci.2022.10.007_bib61) 2021; 9 Benito-Villalvilla (10.1016/j.jaci.2022.10.007_bib8) 2022; 149 Pennington (10.1016/j.jaci.2022.10.007_bib91) 2021; 12 Golebski (10.1016/j.jaci.2022.10.007_bib10) 2021; 54 Dantzer (10.1016/j.jaci.2022.10.007_bib35) 2022; 149 Padró (10.1016/j.jaci.2022.10.007_bib42) 2022; 10 Yonekura (10.1016/j.jaci.2022.10.007_bib72) 2021; 9 Badi (10.1016/j.jaci.2022.10.007_bib56) 2022; 149 Mikus (10.1016/j.jaci.2022.10.007_bib18) 2021; 147 Yu (10.1016/j.jaci.2022.10.007_bib86) 2020; 98 Farraia (10.1016/j.jaci.2022.10.007_bib74) 2022; 77 Schmid (10.1016/j.jaci.2022.10.007_bib14) 2021; 76 Song (10.1016/j.jaci.2022.10.007_bib83) 2017; 312 Zhu (10.1016/j.jaci.2022.10.007_bib38) 2022; 36 Jones (10.1016/j.jaci.2022.10.007_bib31) 2017; 139 Braithwaite (10.1016/j.jaci.2022.10.007_bib55) 2021; 148 Busse (10.1016/j.jaci.2022.10.007_bib30) 2021; 58 Langer (10.1016/j.jaci.2022.10.007_bib37) 2022; 10 Gevaert (10.1016/j.jaci.2022.10.007_bib45) 2022; 149 Trichot (10.1016/j.jaci.2022.10.007_bib25) 2021; 147 Yoneyama (10.1016/j.jaci.2022.10.007_bib6) 2021; 147 Graff (10.1016/j.jaci.2022.10.007_bib65) 2022; 10 |
| References_xml | – volume: 79 start-page: 347 year: 2022 ident: bib89 article-title: Circulating SSEA-1+ stem cell-mediated tissue repair in allergic airway inflammation publication-title: Cell Mol Life Sci – volume: 149 start-page: 212 year: 2022 end-page: 222.e9 ident: bib8 article-title: Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring publication-title: J Allergy Clin Immunol – volume: 147 start-page: 663 year: 2021 end-page: 676 ident: bib2 article-title: Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy publication-title: J Allergy Clin Immunol – volume: 385 start-page: 2230 year: 2021 end-page: 2240 ident: bib48 article-title: Dupilumab in children with uncontrolled moderate-to-severe asthma publication-title: N Engl J Med – volume: 147 start-page: 1865 year: 2021 end-page: 1877 ident: bib3 article-title: Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy publication-title: J Allergy Clin Immunol – volume: 32 start-page: S71 year: 2021 end-page: S80 ident: bib24 article-title: Profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab publication-title: Dermatitis – volume: 10 start-page: 539 year: 2022 end-page: 549.e7 ident: bib37 article-title: Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled trial publication-title: J Allergy Clin Immunol Pract – volume: 10 start-page: 133 year: 2022 ident: bib85 article-title: The potential of exosomes in allergy immunotherapy publication-title: Vaccines (Basel) – volume: 147 start-page: 1020 year: 2021 end-page: 1030.e10 ident: bib36 article-title: A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized phase III clinical trial publication-title: J Allergy Clin Immunol – volume: 148 start-page: 783 year: 2021 end-page: 789 ident: bib55 article-title: Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial publication-title: J Allergy Clin Immunol – volume: 54 start-page: 291 year: 2021 end-page: 307.e7 ident: bib10 article-title: Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response publication-title: Immunity – volume: 76 start-page: 1528 year: 2021 end-page: 1538 ident: bib14 article-title: Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients publication-title: Allergy – volume: 9 start-page: 216 year: 2021 end-page: 224.e1 ident: bib33 article-title: Improvements in quality of life in children following epicutaneous immunotherapy (EPIT) for peanut allergy in the PEPITES and PEOPLE studies publication-title: J Allergy Clin Immunol Pract – volume: 15 start-page: 11192 year: 2021 end-page: 11201 ident: bib78 article-title: A GATA3 targeting nucleic acid nanocapsule for in vivo gene regulation in asthma publication-title: ACS Nano – reference: Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2021;9:1299-312. Erratum in: Lancet Respir Med 2021;9:e106. – volume: 32 start-page: 1287 year: 2021 end-page: 1295 ident: bib62 article-title: Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab: real life survey from a Spanish registry publication-title: Pediatr Allergy Immunol – volume: 58 year: 2021 ident: bib21 article-title: COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy publication-title: Eur Respir J – volume: 147 start-page: 1004 year: 2021 end-page: 1010.e2 ident: bib46 article-title: A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis publication-title: J Allergy Clin Immunol – volume: 147 start-page: 233 year: 2021 end-page: 243 ident: bib29 article-title: Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients publication-title: J Allergy Clin Immunol – volume: 126 start-page: 367 year: 2021 end-page: 377.e5 ident: bib39 article-title: A randomized trial of subcutaneous allergy immunotherapy in inner-city children with asthma less than 4 years of age publication-title: Ann Allergy Asthma Immunol – volume: 149 start-page: 1373 year: 2022 end-page: 1382.e12 ident: bib12 article-title: Allergen-specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts publication-title: J Allergy Clin Immunol – volume: 133 start-page: 1709 year: 2014 end-page: 1719.e8 ident: bib90 article-title: Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells publication-title: J Allergy Clin Immunol – volume: 230 year: 2021 ident: bib4 article-title: Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy publication-title: Clin Immunol – volume: 147 start-page: 2271 year: 2021 end-page: 2280.e8 ident: bib26 article-title: The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes publication-title: J Allergy Clin Immunol – volume: 76 start-page: 90 year: 2021 end-page: 113 ident: bib79 article-title: Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—an EAACI position paper of the Task Force on Immunopharmacology (TIPCO) publication-title: Allergy – volume: 139 start-page: 1242 year: 2017 end-page: 1252.e9 ident: bib31 article-title: Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults publication-title: J Allergy Clin Immunol – volume: 9 start-page: 4103 year: 2021 end-page: 4116.e14 ident: bib72 article-title: Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets publication-title: J Allergy Clin Immunol Pract – reference: Laoubi L, Lacoffrette M, Valsesia S, Lenief V, Guironnet-Paquet A, Mosnier A, et al. Epicutaneous allergen immunotherapy induces a profound and selective modulation in skin dendritic-cell subsets [published online ahead of print June 30, 2022]. J Allergy Clin Immunol. – volume: 32 start-page: 1654 year: 2021 end-page: 1662 ident: bib15 article-title: Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: evidence from three years’ immunotherapy publication-title: Pediatr Allergy Immunol – volume: 149 start-page: 1691 year: 2022 end-page: 1701.e9 ident: bib11 article-title: CD38+ B cells affect immunotherapy for allergic rhinitis publication-title: J Allergy Clin Immunol – volume: 76 start-page: 2621 year: 2021 end-page: 2624 ident: bib49 article-title: Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST publication-title: Allergy – volume: 9 start-page: 1288 year: 2021 end-page: 1298 ident: bib53 article-title: Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial publication-title: Lancet Respir Med – volume: 147 start-page: 1507 year: 2021 end-page: 1510.e8 ident: bib9 article-title: IL-10-producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy publication-title: J Allergy Clin Immunol – volume: 149 start-page: 1018 year: 2022 end-page: 1030.e11 ident: bib20 article-title: A novel functional mast cell assay for the detection of allergies publication-title: J Allergy Clin Immunol – volume: 9 start-page: 3221 year: 2021 end-page: 3223.e5 ident: bib58 article-title: Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: a noninterventional, open-label study publication-title: J Allergy Clin Immunol Pract – volume: 10 start-page: e585 year: 2022 ident: bib42 article-title: Effectiveness and safety of a microcrystalline tyrosine-adjuvanted publication-title: Immun Inflamm Dis – volume: 76 start-page: 220 year: 2021 end-page: 227 ident: bib64 article-title: Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era publication-title: Thorax – volume: 10 start-page: 467 year: 2022 end-page: 477 ident: bib65 article-title: Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry publication-title: J Allergy Clin Immunol Pract – volume: 12 start-page: 7069 year: 2021 ident: bib91 article-title: Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex publication-title: Nat Commun – volume: 149 start-page: 884 year: 2022 end-page: 886 ident: bib69 article-title: Managing risk of anaphylaxis in patients receiving allergen immunotherapy: assessing benefit versus risk publication-title: J Allergy Clin Immunol – volume: 147 start-page: 756 year: 2021 end-page: 759 ident: bib25 article-title: TH cell diversity and response to dupilumab in patients with atopic dermatitis publication-title: J Allergy Clin Immunol – volume: 12 year: 2021 ident: bib73 article-title: Preventive administration of non-allergenic Bet v 1 peptides reduces allergic sensitization to major birch pollen allergen, Bet v 1 publication-title: Front Immunol – volume: 148 start-page: 1061 year: 2021 end-page: 1071.e11 ident: bib5 article-title: Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy publication-title: J Allergy Clin Immunol – volume: 149 start-page: 89 year: 2022 end-page: 101 ident: bib56 article-title: Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma publication-title: J Allergy Clin Immunol – volume: 149 start-page: 2043 year: 2022 end-page: 2052.e9 ident: bib34 article-title: Safety of peanut ( publication-title: J Allergy Clin Immunol – volume: 5 start-page: 274 year: 2021 end-page: 286 ident: bib75 article-title: Status report on the atopic dermatitis registry TREATgermany publication-title: Allergol Select – volume: 13 year: 2022 ident: bib59 article-title: Current strategies to modulate regulatory T cell activity in allergic inflammation publication-title: Front Immunol – volume: 9 start-page: 2715 year: 2021 end-page: 2724.e5 ident: bib66 article-title: Mepolizumab and oral corticosteroid stewardship: data from the Australian Mepolizumab Registry publication-title: J Allergy Clin Immunol Pract – volume: 147 start-page: 992 year: 2021 end-page: 1003.e5 ident: bib32 article-title: Epicutaneous immunotherapy for treatment of peanut allergy: follow-up from the Consortium for Food Allergy Research publication-title: J Allergy Clin Immunol – volume: 178 year: 2021 ident: bib63 article-title: Geographical and socioeconomic differences in compliance with and access to allergen immunotherapy in Denmark: a nationwide registry-based study—1998-2016 publication-title: Respir Med – volume: 123 year: 2020 ident: bib81 article-title: Chimeric antigen receptor T cell therapy: applications and challenges in treatment of allergy and asthma publication-title: Biomed Pharmacother – volume: 11 start-page: 613 year: 2021 ident: bib16 article-title: Metabolomics reveals process of allergic rhinitis patients with single- and double-species mite subcutaneous immunotherapy publication-title: Metabolites – volume: 36 start-page: 245 year: 2022 end-page: 252 ident: bib38 article-title: Efficacy and safety of subcutaneous immunotherapy for local allergic rhinitis: a meta-analysis of randomized controlled trials publication-title: Am J Rhinol Allergy – volume: 131 year: 2021 ident: bib88 article-title: Basal epithelial stem cells cross an alarmin checkpoint for postviral lung disease publication-title: J Clin Invest – volume: 78 start-page: 872 year: 2018 end-page: 881.e6 ident: bib60 article-title: Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial publication-title: J Am Acad Dermatol – volume: 147 start-page: 1011 year: 2021 end-page: 1019 ident: bib40 article-title: Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial publication-title: J Allergy Clin Immunol – volume: 21 start-page: 576 year: 2021 end-page: 582 ident: bib77 article-title: Nanoparticles in allergen immunotherapy publication-title: Curr Opin Allergy Clin Immunol – volume: 149 start-page: 1309 year: 2022 end-page: 1317.e12 ident: bib47 article-title: Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial publication-title: J Allergy Clin Immunol – volume: 148 start-page: 790 year: 2021 end-page: 798 ident: bib54 article-title: Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial publication-title: J Allergy Clin Immunol – volume: 582 start-page: 416 year: 2020 end-page: 420 ident: bib80 article-title: CRISPR screen in regulatory T cells reveals modulators of Foxp3 publication-title: Nature – volume: 147 start-page: 1 year: 2021 end-page: 13 ident: bib68 article-title: Integrating oral immunotherapy into clinical practice publication-title: J Allergy Clin Immunol – volume: 51 start-page: 1648 year: 2021 end-page: 1652 ident: bib28 article-title: Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab publication-title: Clin Exp Allergy – volume: 182 start-page: 524 year: 2021 end-page: 534 ident: bib44 article-title: Accelerated dose escalation with 3 injections of an aluminum hydroxide-adsorbed allergoid preparation of 6 grasses is safe for children and adolescents with moderate to severe allergic rhinitis publication-title: Int Arch Allergy Immunol – volume: 385 start-page: 1669 year: 2021 end-page: 1679 ident: bib52 article-title: Risankizumab in severe asthma—a phase 2a, placebo-controlled trial publication-title: N Engl J Med – volume: 9 start-page: 359 year: 2021 ident: bib76 article-title: Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines publication-title: Vaccines (Basel) – volume: 98 start-page: 639 year: 2020 end-page: 649 ident: bib86 article-title: Specific antigen-guiding exosomes inhibit food allergies by inducing regulatory T cells publication-title: Immunol Cell Biol – volume: 147 start-page: 772 year: 2021 end-page: 775 ident: bib22 article-title: Identification of whole blood gene expressions correlated with responsiveness to benralizumab publication-title: J Allergy Clin Immunol – volume: 9 year: 2021 ident: bib23 article-title: Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma? publication-title: Respirol Case Rep – volume: 9 start-page: 1349 year: 2021 end-page: 1356.e1 ident: bib61 article-title: First real-world effectiveness analysis of preschool peanut oral immunotherapy publication-title: J Allergy Clin Immunol Pract – volume: 147 start-page: 1063 year: 2021 end-page: 1076.e9 ident: bib6 article-title: Notch signaling contributes to the establishment of sustained unresponsiveness to food allergens by oral immunotherapy publication-title: J Allergy Clin Immunol – volume: 12 start-page: 208 year: 2021 ident: bib82 article-title: Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing publication-title: Genes (Basel) – volume: 77 start-page: 1719 year: 2022 end-page: 1735 ident: bib74 article-title: Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis of randomized and non-randomized controlled studies publication-title: Allergy – volume: 147 start-page: 1077 year: 2021 end-page: 1086 ident: bib18 article-title: Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy publication-title: J Allergy Clin Immunol – volume: 58 year: 2021 ident: bib30 article-title: Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma publication-title: Eur Respir J – volume: 149 start-page: 1383 year: 2022 end-page: 1391.e17 ident: bib35 article-title: Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: a randomized, double-blind, placebo-controlled phase 2 trial publication-title: J Allergy Clin Immunol – volume: 147 start-page: 2295 year: 2021 end-page: 2304.e12 ident: bib27 article-title: Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab publication-title: J Allergy Clin Immunol – volume: 24 start-page: 628 year: 2019 end-page: 637 ident: bib84 article-title: Applications of CRISPR systems in respiratory health: entering a new ‘red pen’ era in genome editing publication-title: Respirology – volume: 9 start-page: 1864 year: 2021 end-page: 1870 ident: bib13 article-title: Serum periostin as a biomarker for predicting clinical response to house dust mite sublingual immunotherapy in allergic rhinitis publication-title: J Allergy Clin Immunol Pract – volume: 385 start-page: 1656 year: 2021 end-page: 1668 ident: bib51 article-title: Efficacy and safety of itepekimab in patients with moderate-to-severe asthma publication-title: N Engl J Med – volume: 76 start-page: 456 year: 2021 end-page: 470 ident: bib1 article-title: Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy publication-title: Allergy – volume: 76 start-page: 2259 year: 2021 end-page: 2261 ident: bib70 article-title: Optimization of a transmural care pathway for allergen immunotherapy to primary care by an integrated personal eHealth environment publication-title: Allergy – reference: Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract 2021;9:2680-8.e7. Erratum in: J Allergy Clin Immunol Pract 2021;9:4182. – reference: . – volume: 312 start-page: L334 year: 2017 end-page: L347 ident: bib83 article-title: Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells publication-title: Am J Physiol Lung Cell Mol Physiol – volume: 148 start-page: 266 year: 2021 end-page: 271.e2 ident: bib50 article-title: Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years of treatment publication-title: J Allergy Clin Immunol – volume: 28 start-page: 79 year: 2021 end-page: 95.e8 ident: bib87 article-title: Derivation of airway basal stem cells from human pluripotent stem cells publication-title: Cell Stem Cell – volume: 149 start-page: 833 year: 2022 end-page: 843 ident: bib17 article-title: Which patients with asthma are most likely to benefit from allergen immunotherapy? publication-title: J Allergy Clin Immunol – volume: 77 start-page: 3096 year: 2022 end-page: 3107 ident: bib41 article-title: First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy publication-title: Allergy – volume: 92 year: 2021 ident: bib43 article-title: Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma publication-title: Acta Biomed – volume: 129 start-page: 1493 year: 2019 end-page: 1503 ident: bib19 article-title: Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases publication-title: J Clin Invest – volume: 149 start-page: 189 year: 2022 end-page: 199 ident: bib45 article-title: Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study publication-title: J Allergy Clin Immunol – volume: 51 start-page: 821 year: 2021 end-page: 828 ident: bib71 article-title: @IT2020: an innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis publication-title: Clin Exp Allergy – volume: 76 start-page: 456 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib1 article-title: Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy publication-title: Allergy doi: 10.1111/all.14639 – volume: 147 start-page: 1507 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib9 article-title: IL-10-producing innate lymphoid cells increased in patients with house dust mite allergic rhinitis following immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.10.029 – volume: 5 start-page: 274 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib75 article-title: Status report on the atopic dermatitis registry TREATgermany publication-title: Allergol Select doi: 10.5414/ALX02262E – volume: 12 start-page: 7069 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib91 article-title: Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex publication-title: Nat Commun doi: 10.1038/s41467-021-27397-z – volume: 12 start-page: 208 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib82 article-title: Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing publication-title: Genes (Basel) doi: 10.3390/genes12020208 – volume: 139 start-page: 1242 year: 2017 ident: 10.1016/j.jaci.2022.10.007_bib31 article-title: Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.08.017 – volume: 15 start-page: 11192 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib78 article-title: A GATA3 targeting nucleic acid nanocapsule for in vivo gene regulation in asthma publication-title: ACS Nano doi: 10.1021/acsnano.0c07781 – ident: 10.1016/j.jaci.2022.10.007_bib57 doi: 10.1016/S2213-2600(21)00226-5 – volume: 147 start-page: 1020 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib36 article-title: A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized phase III clinical trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.07.036 – volume: 92 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib43 article-title: Evaluation of safety and tolerability of a rush up-dosing allergen-specific immunotherapy with grass pollen, birch, hazel, and alder allergoid in children with allergic rhinoconjunctivitis, with or without asthma publication-title: Acta Biomed – volume: 131 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib88 article-title: Basal epithelial stem cells cross an alarmin checkpoint for postviral lung disease publication-title: J Clin Invest doi: 10.1172/JCI149336 – volume: 77 start-page: 1719 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib74 article-title: Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis of randomized and non-randomized controlled studies publication-title: Allergy doi: 10.1111/all.15295 – volume: 147 start-page: 1063 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib6 article-title: Notch signaling contributes to the establishment of sustained unresponsiveness to food allergens by oral immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.07.011 – volume: 149 start-page: 833 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib17 article-title: Which patients with asthma are most likely to benefit from allergen immunotherapy? publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2022.01.011 – volume: 76 start-page: 220 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib64 article-title: Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era publication-title: Thorax doi: 10.1136/thoraxjnl-2020-215168 – volume: 12 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib73 article-title: Preventive administration of non-allergenic Bet v 1 peptides reduces allergic sensitization to major birch pollen allergen, Bet v 1 publication-title: Front Immunol doi: 10.3389/fimmu.2021.744544 – volume: 148 start-page: 266 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib50 article-title: Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years of treatment publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.02.009 – volume: 13 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib59 article-title: Current strategies to modulate regulatory T cell activity in allergic inflammation publication-title: Front Immunol doi: 10.3389/fimmu.2022.912529 – volume: 129 start-page: 1493 year: 2019 ident: 10.1016/j.jaci.2022.10.007_bib19 article-title: Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases publication-title: J Clin Invest doi: 10.1172/JCI124611 – volume: 148 start-page: 790 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib54 article-title: Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.03.044 – volume: 385 start-page: 1669 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib52 article-title: Risankizumab in severe asthma—a phase 2a, placebo-controlled trial publication-title: N Engl J Med doi: 10.1056/NEJMoa2030880 – volume: 147 start-page: 992 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib32 article-title: Epicutaneous immunotherapy for treatment of peanut allergy: follow-up from the Consortium for Food Allergy Research publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.11.027 – volume: 123 year: 2020 ident: 10.1016/j.jaci.2022.10.007_bib81 article-title: Chimeric antigen receptor T cell therapy: applications and challenges in treatment of allergy and asthma publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2019.109685 – volume: 147 start-page: 2271 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib26 article-title: The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.02.038 – volume: 312 start-page: L334 year: 2017 ident: 10.1016/j.jaci.2022.10.007_bib83 article-title: Targeted epigenetic editing of SPDEF reduces mucus production in lung epithelial cells publication-title: Am J Physiol Lung Cell Mol Physiol doi: 10.1152/ajplung.00059.2016 – volume: 9 start-page: 216 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib33 article-title: Improvements in quality of life in children following epicutaneous immunotherapy (EPIT) for peanut allergy in the PEPITES and PEOPLE studies publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.08.015 – volume: 9 start-page: 4103 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib72 article-title: Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.06.060 – volume: 54 start-page: 291 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib10 article-title: Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response publication-title: Immunity doi: 10.1016/j.immuni.2020.12.013 – volume: 51 start-page: 1648 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib28 article-title: Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab publication-title: Clin Exp Allergy doi: 10.1111/cea.14014 – volume: 9 start-page: 1288 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib53 article-title: Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00167-3 – volume: 149 start-page: 1309 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib47 article-title: Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.08.030 – volume: 148 start-page: 1061 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib5 article-title: Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.03.030 – volume: 147 start-page: 1 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib68 article-title: Integrating oral immunotherapy into clinical practice publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.11.011 – volume: 58 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib30 article-title: Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma publication-title: Eur Respir J doi: 10.1183/13993003.04605-2020 – volume: 10 start-page: e585 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib42 article-title: Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: a real-life prospective observational study publication-title: Immun Inflamm Dis doi: 10.1002/iid3.585 – volume: 385 start-page: 1656 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib51 article-title: Efficacy and safety of itepekimab in patients with moderate-to-severe asthma publication-title: N Engl J Med doi: 10.1056/NEJMoa2024257 – volume: 149 start-page: 1691 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib11 article-title: CD38+ B cells affect immunotherapy for allergic rhinitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2022.01.012 – volume: 32 start-page: 1287 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib62 article-title: Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab: real life survey from a Spanish registry publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.13517 – volume: 36 start-page: 245 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib38 article-title: Efficacy and safety of subcutaneous immunotherapy for local allergic rhinitis: a meta-analysis of randomized controlled trials publication-title: Am J Rhinol Allergy doi: 10.1177/19458924211050547 – volume: 230 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib4 article-title: Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy publication-title: Clin Immunol doi: 10.1016/j.clim.2021.108820 – volume: 182 start-page: 524 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib44 article-title: Accelerated dose escalation with 3 injections of an aluminum hydroxide-adsorbed allergoid preparation of 6 grasses is safe for children and adolescents with moderate to severe allergic rhinitis publication-title: Int Arch Allergy Immunol doi: 10.1159/000512561 – volume: 147 start-page: 233 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib29 article-title: Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.08.039 – volume: 76 start-page: 2259 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib70 article-title: Optimization of a transmural care pathway for allergen immunotherapy to primary care by an integrated personal eHealth environment publication-title: Allergy doi: 10.1111/all.14753 – volume: 32 start-page: S71 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib24 article-title: Profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab publication-title: Dermatitis doi: 10.1097/DER.0000000000000764 – volume: 147 start-page: 756 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib25 article-title: TH cell diversity and response to dupilumab in patients with atopic dermatitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.05.037 – volume: 32 start-page: 1654 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib15 article-title: Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: evidence from three years’ immunotherapy publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.13569 – volume: 78 start-page: 872 year: 2018 ident: 10.1016/j.jaci.2022.10.007_bib60 article-title: Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2018.01.016 – volume: 147 start-page: 772 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib22 article-title: Identification of whole blood gene expressions correlated with responsiveness to benralizumab publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.08.004 – volume: 133 start-page: 1709 year: 2014 ident: 10.1016/j.jaci.2022.10.007_bib90 article-title: Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.02.005 – volume: 149 start-page: 212 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib8 article-title: Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.06.012 – volume: 149 start-page: 1018 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib20 article-title: A novel functional mast cell assay for the detection of allergies publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.08.006 – volume: 10 start-page: 133 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib85 article-title: The potential of exosomes in allergy immunotherapy publication-title: Vaccines (Basel) doi: 10.3390/vaccines10010133 – volume: 126 start-page: 367 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib39 article-title: A randomized trial of subcutaneous allergy immunotherapy in inner-city children with asthma less than 4 years of age publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2020.12.016 – volume: 147 start-page: 2295 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib27 article-title: Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.02.039 – volume: 10 start-page: 467 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib65 article-title: Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.09.023 – ident: 10.1016/j.jaci.2022.10.007_bib7 doi: 10.1016/j.jaci.2022.05.025 – volume: 147 start-page: 1865 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib3 article-title: Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.08.042 – volume: 149 start-page: 189 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib45 article-title: Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.05.039 – volume: 10 start-page: 539 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib37 article-title: Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled trial publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.10.060 – volume: 21 start-page: 576 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib77 article-title: Nanoparticles in allergen immunotherapy publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0000000000000782 – volume: 51 start-page: 821 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib71 article-title: @IT2020: an innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis publication-title: Clin Exp Allergy doi: 10.1111/cea.13867 – volume: 9 start-page: 2715 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib66 article-title: Mepolizumab and oral corticosteroid stewardship: data from the Australian Mepolizumab Registry publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.01.028 – volume: 147 start-page: 1011 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib40 article-title: Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.07.002 – volume: 9 start-page: 1864 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib13 article-title: Serum periostin as a biomarker for predicting clinical response to house dust mite sublingual immunotherapy in allergic rhinitis publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.11.046 – volume: 149 start-page: 2043 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib34 article-title: Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: pooled summary of phase 3 and extension trials publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.12.780 – volume: 98 start-page: 639 year: 2020 ident: 10.1016/j.jaci.2022.10.007_bib86 article-title: Specific antigen-guiding exosomes inhibit food allergies by inducing regulatory T cells publication-title: Immunol Cell Biol doi: 10.1111/imcb.12347 – volume: 178 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib63 article-title: Geographical and socioeconomic differences in compliance with and access to allergen immunotherapy in Denmark: a nationwide registry-based study—1998-2016 publication-title: Respir Med doi: 10.1016/j.rmed.2021.106332 – volume: 582 start-page: 416 year: 2020 ident: 10.1016/j.jaci.2022.10.007_bib80 article-title: CRISPR screen in regulatory T cells reveals modulators of Foxp3 publication-title: Nature doi: 10.1038/s41586-020-2246-4 – volume: 58 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib21 article-title: COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy publication-title: Eur Respir J doi: 10.1183/13993003.03969-2020 – volume: 76 start-page: 1528 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib14 article-title: Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients publication-title: Allergy doi: 10.1111/all.14264 – volume: 147 start-page: 1077 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib18 article-title: Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.08.002 – volume: 9 start-page: 1349 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib61 article-title: First real-world effectiveness analysis of preschool peanut oral immunotherapy publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.10.045 – volume: 147 start-page: 1004 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib46 article-title: A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.11.005 – volume: 385 start-page: 2230 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib48 article-title: Dupilumab in children with uncontrolled moderate-to-severe asthma publication-title: N Engl J Med doi: 10.1056/NEJMoa2106567 – volume: 147 start-page: 663 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib2 article-title: Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.10.035 – volume: 149 start-page: 89 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib56 article-title: Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.04.010 – volume: 149 start-page: 1383 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib35 article-title: Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: a randomized, double-blind, placebo-controlled phase 2 trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.10.023 – volume: 28 start-page: 79 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib87 article-title: Derivation of airway basal stem cells from human pluripotent stem cells publication-title: Cell Stem Cell doi: 10.1016/j.stem.2020.09.017 – volume: 148 start-page: 783 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib55 article-title: Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.02.042 – volume: 9 start-page: 3221 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib58 article-title: Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: a noninterventional, open-label study publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.03.045 – ident: 10.1016/j.jaci.2022.10.007_bib67 doi: 10.1016/j.jaip.2021.02.059 – volume: 149 start-page: 1373 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib12 article-title: Allergen-specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2021.09.029 – volume: 77 start-page: 3096 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib41 article-title: First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy publication-title: Allergy doi: 10.1111/all.15374 – volume: 149 start-page: 884 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib69 article-title: Managing risk of anaphylaxis in patients receiving allergen immunotherapy: assessing benefit versus risk publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2022.01.009 – volume: 9 start-page: 359 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib76 article-title: Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines publication-title: Vaccines (Basel) doi: 10.3390/vaccines9040359 – volume: 76 start-page: 90 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib79 article-title: Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—an EAACI position paper of the Task Force on Immunopharmacology (TIPCO) publication-title: Allergy doi: 10.1111/all.14478 – volume: 76 start-page: 2621 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib49 article-title: Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST publication-title: Allergy doi: 10.1111/all.14872 – volume: 11 start-page: 613 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib16 article-title: Metabolomics reveals process of allergic rhinitis patients with single- and double-species mite subcutaneous immunotherapy publication-title: Metabolites doi: 10.3390/metabo11090613 – volume: 79 start-page: 347 year: 2022 ident: 10.1016/j.jaci.2022.10.007_bib89 article-title: Circulating SSEA-1+ stem cell-mediated tissue repair in allergic airway inflammation publication-title: Cell Mol Life Sci doi: 10.1007/s00018-022-04366-3 – volume: 24 start-page: 628 year: 2019 ident: 10.1016/j.jaci.2022.10.007_bib84 article-title: Applications of CRISPR systems in respiratory health: entering a new ‘red pen’ era in genome editing publication-title: Respirology doi: 10.1111/resp.13527 – volume: 9 year: 2021 ident: 10.1016/j.jaci.2022.10.007_bib23 article-title: Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma? publication-title: Respirol Case Rep doi: 10.1002/rcr2.717 |
| SSID | ssj0009389 |
| Score | 2.5032256 |
| SecondaryResourceType | review_article |
| Snippet | Through its disease-modifying potential, immunotherapy is the keystone to curing allergic diseases. Allergen immunotherapy, applied for more than a century, is... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1279 |
| SubjectTerms | Allergen biologicals biomarkers endotypes immunotherapy theratype |
| Title | Immunotherapy: State-of-the-art review of therapies and theratypes |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0091674922013744 https://dx.doi.org/10.1016/j.jaci.2022.10.007 https://www.ncbi.nlm.nih.gov/pubmed/36328808 https://www.proquest.com/docview/2732537360 |
| Volume | 150 |
| WOSCitedRecordID | wos000942834800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1097-6825 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009389 issn: 0091-6749 databaseCode: AIEXJ dateStart: 20200301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbKhhAvE3c6YAoSb8hVYie1w1tBQxtSJySGqHiJHNce7bpk6mXaz-GncnyJUyo62AMvUWTFzuV8Pv7sfOcYoTeUSvN7BrwfS0ucKsaw0LnEgmaxLLXkQsR2swl2csJHo_xzp_OziYW5mrGq4tfX-eV_NTWUgbFN6OwtzB0ahQI4B6PDEcwOx38y_LGJ-PBxVTadk-WTuNYYyowQbi1cxV0Fk-VGSAl4gInpYgtlNfuuzH3GphBSObH3W1-cH5yZLNHW-9SiCn7_u7pQs3OBv00sg82kOnfRQmdG1Nxe9-WHuJhakcGwhlNgxEe9IPRZLZ2sYCjmPs2wX7IgZE3-4d1wnuA-c7lKgxt2CWg93tadakLcfjN-gIYRlf_R-bt1iGlvKuSkZ-7bs7o91g51ze_9jREw6BIbydu0MG0Upg0oKGy6gl3Cshxc_-7g-HD0qU3sTLmbYvlX8oFZTkO4-STbyM-2yY0lOacP0J43dTRwqHqIOqp6hO4Nvf7iMXr_G7jeRZvQihy0olpHAVoRoCVqofUEff14ePrhCPtdOLBMGV1inVCdyUSSMh6rcqwo1yRJ9TjXY6JKUQKHZWlGgTgyUiro-2NGWRpLJhIhhcjoU7RT1ZV6jiLNS61ILrNEpMCDhKAC-KFQCZcxkQntoqT5PIX0KerNTimzYrthuuhtqHPpErTceDVtvnrR9BMYLAuA0I21slDLE1NHOP9a73Vj2AK8tvkVJypVrxYFTBpIRhntx130zFk8PD3tU0B4zPdv9WYv0P22q71EO8v5Sr1Cd-XVcrKYH6A7bMQPPHZ_AdB_wyo |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunotherapy%3A+State-of-the-art+review+of+therapies+and+theratypes&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Agache%2C+Ioana&rft.au=Zemelka-Wi%C4%85cek%2C+Magdalena&rft.au=Shamji%2C+Mohamed+H.&rft.au=Jutel%2C+Marek&rft.date=2022-12-01&rft.issn=0091-6749&rft.volume=150&rft.issue=6&rft.spage=1279&rft.epage=1288&rft_id=info:doi/10.1016%2Fj.jaci.2022.10.007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jaci_2022_10_007 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon |